Literature DB >> 33387351

DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway.

X Hu1, S Chen1, C Xie1, Z Li1, Z Wu1, Z You2.   

Abstract

PURPOSE: Papillary thyroid carcinoma (PTC) is characterized by epithelial malignancy and is the most prevalent thyroid neoplasm with the best overall prognosis. Notably, recently published studies have indicated remarkably high expression of dipeptidyl peptidase 4 (DPP4) in PTC. However, the underlying molecular mechanism and regulatory factors of PTC progression remain unknown. Therefore, the current study aimed to elucidate the effects of DPP4 gene silencing on PTC and further investigated whether the mechanism of PTC progression is related to the mitogen-activated protein kinase (MAPK) pathway.
METHODS: Herein, microarray-based gene expression profiling of PTC was conducted to identify the differentially expressed genes between tumor thyroid tissue and normal thyroid tissue as well as the underlying signaling pathway involved in PTC pathogenesis. Moreover, protein quantification was performed to assess the protein expression of DPP4 in PTC tissues collected from 65 patients. In addition, DPP4 was silenced in PTC cell lines (GLAG-66 and TPC-1) through siRNA-mediated DPP4 knockdown or sitagliptin (inhibitor of DPP4)-mediated inhibition to assess the effects of DPP4 on the MAPK pathway and cellular processes, including proliferation, apoptosis, and epithelial-to-mesenchymal transition (EMT).
RESULTS: Intriguingly, our data revealed markedly high expression of DPP4 in PTC tissues. However, in GLAG-66 and TPC-1 cells, the silencing of DPP4 resulted in significantly reduced expression of ERK1/2, JNK1, P38 MAPK, VEGF, FGFR-1, TGF-β1, Snail, HIF-1α, N-cadherin, and Bcl-2 along with reduced phosphorylation of ERK1/2, JNK1, and P38 MAPK, whereas the expression of E-cadherin and Bax was increased. Furthermore, DPP4 silencing was found to hinder cell proliferation and potentiate cell apoptosis.
CONCLUSION: Collectively, the present study demonstrated that DPP4 gene silencing inhibits PTC cell proliferation and EMT and promotes cell apoptosis via suppression of the MAPK pathway, thus highlighting a possible regulatory pathway in PTC progression.
© 2021. Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Apoptosis; DPP4; Epithelial-to-mesenchymal transition; MAPK pathway; Papillary thyroid carcinoma; Proliferation

Mesh:

Substances:

Year:  2021        PMID: 33387351     DOI: 10.1007/s40618-020-01455-7

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  38 in total

1.  Gene expression in papillary thyroid carcinoma reveals highly consistent profiles.

Authors:  Y Huang; M Prasad; W J Lemon; H Hampel; F A Wright; K Kornacker; V LiVolsi; W Frankel; R T Kloos; C Eng; N S Pellegata; A de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 2.  [PAPILLARY THYROID CARCINOMA TREATMENT - IS THE PENDULUM SHIFTING?]

Authors:  Sagit Stern; Elad Dagan; Eran E Alon; Ziv Gil; Gideon Bachar
Journal:  Harefuah       Date:  2016-08

3.  The role of dipeptidyl peptidase 4 (DPP4) in the preservation of renal function: DPP4 involvement in hemoglobin expression.

Authors:  Youichi Sato; Takanobu Kamada; Aiko Yamauchi
Journal:  J Endocrinol       Date:  2014-08-13       Impact factor: 4.286

Review 4.  Papillary thyroid carcinoma: an update.

Authors:  Virginia A LiVolsi
Journal:  Mod Pathol       Date:  2011-04       Impact factor: 7.842

5.  DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.

Authors:  Lorenzo L F Glorie; Anja Verhulst; Veerle Matheeussen; Lesley Baerts; Joanna Magielse; Nina Hermans; Patrick C D'Haese; Ingrid De Meester; Annelies De Beuf
Journal:  Am J Physiol Renal Physiol       Date:  2012-06-20

6.  [Expression of DPP4 gene in papillary thyroid carcinoma].

Authors:  Joanna Ozóg; Michał Jarzab; Agnieszka Pawlaczek; Małgorzata Oczko-Wojciechowska; Jan Włoch; Józef Roskosz; Elzbieta Gubała
Journal:  Endokrynol Pol       Date:  2006       Impact factor: 1.582

Review 7.  Controversies in primary treatment of low-risk papillary thyroid cancer.

Authors:  Donald S A McLeod; Anna M Sawka; David S Cooper
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

8.  Papillary thyroid carcinoma: factors influencing recurrence and survival.

Authors:  Antonio Toniato; Isabella Boschin; Dario Casara; Renzo Mazzarotto; Domenico Rubello; Mariarosa Pelizzo
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

Review 9.  Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations.

Authors:  Mardiaty Iryani Abdullah; Sarni Mat Junit; Khoon Leong Ng; Jaime Jacqueline Jayapalan; Barani Karikalan; Onn Haji Hashim
Journal:  Int J Med Sci       Date:  2019-02-28       Impact factor: 3.738

10.  Nationwide cohort study on the epidemiology and survival outcomes of thyroid cancer.

Authors:  Fu-Chao Liu; Huan-Tang Lin; Shu-Fu Lin; Chang-Fu Kuo; Ting-Ting Chung; Huang-Ping Yu
Journal:  Oncotarget       Date:  2017-07-22
View more
  3 in total

1.  Identification of Immune-Cell-Related Prognostic Biomarkers of Esophageal Squamous Cell Carcinoma Based on Tumor Microenvironment.

Authors:  Yiyao Cui; Ruiqin Hou; Xiaoshuo Lv; Feng Wang; Zhaoyan Yu; Yong Cui
Journal:  Front Oncol       Date:  2021-10-25       Impact factor: 6.244

Review 2.  Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Authors:  Emile Verhulst; Delphine Garnier; Ingrid De Meester; Brigitte Bauvois
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

3.  Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma.

Authors:  Song Wang; Shiming Chen; Yufan Ying; Xueyou Ma; Haixiang Shen; Jiangfeng Li; Xiao Wang; Yiwei Lin; Ben Liu; Xiangyi Zheng; Liping Xie
Journal:  Front Cell Dev Biol       Date:  2021-07-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.